Phage Display for the Development of Synthetic Antibodies Targeting Receptor Tyrosine Kinases
Year: 2018
Type: dissertation
Abstract: Receptor tyrosine kinases (RTKs) are single-pass transmembrane receptors that drive the growth and development of human tissue from embryo to adult. Overexpressed RTK family members are present on the surface of cancer cells, making them susceptible to targeting by therapeutic IgGs, molecules that exhibit high affinity and specificity, the ability to recruit the immune system, and the ability to disrupt RTK signaling. Two RTK sub-families, the Eph and ErbB families, have previously been linked to cancer development and progression. Epidermal growth factor receptor (EGFR), the first RTK discovered and a member of the ErbB family, has been extensively validated as tumourigenic and has been the target of four approved therapeutic IgGs. Unfortunately, resistance to existing therapies is common and occurs in 70-90% of patients. Conversely, the Eph receptor family, represented by EphA2 and EphA3 in this study, has been suggested to be either oncogenic or tumour-suppressive, and lacks approved therapeutics. The goal of this project was to examine the epitope-specific effects of these receptors through targeting with high affinity IgGs. I constructed RTK-biased phage-displayed Fab libraries and utilized them to develop hundreds of antibody clones, which were screened for optimal therapeutic and research characteristics. In the first data chapter, I describe the development of anti-Eph receptor IgGs and accompanying proliferation experiments on pancreatic and ovarian tumour cell lines expressing EphA2 and EphA3. I show that cellular Eph receptor context is critical in determining the pharmacological and proliferative response to Eph receptor antagonism, where co-targeting of EphA2 and EphA3 is the most effective therapeutic modality for the treatment of cancers expressing both receptors. In the second data chapter I present the development of two anti-EGFR IgGs, one that targets the same domain as all approved IgG therapeutics, and one that targets a novel epitope. Both IgGs are effective at reducing the proliferation of EGFR-expressing cancers. Importantly, I show that the two IgGs have non-identical anti-proliferative profiles in vitro, revealing a new modality for the treatment of EGFR-positive tumours. My work demonstrates the utility of phage display for the development of IgGs and the therapeutic potential of epitope-specific targeting of RTKs.
Source: TSpace (University of Toronto)
Author: London, Max Eliot
Institution: University of Toronto
Language: English
Subfield: Immunology
Field: Immunology and Microbiology
Domain: Life Sciences
Open Access status: green
OpenAlex ID: W7132948396
